Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 1202

1.

Drosophila PSI controls circadian period and the phase of circadian behavior under temperature cycle via tim splicing.

Foley L, Ling J, Joshi R, Evantal N, Kadener S, Emery P.

Elife. 2019 Nov 8;8. pii: e50063. doi: 10.7554/eLife.50063. [Epub ahead of print]

2.

Comparing psoriatic arthritis low-field magnetic resonance imaging, ultrasound and clinical outcomes: data from the TICOPA trial.

Helliwell PS, Coates LC, Chew NS, Lettieri G, Moverley AR, Freeston JE, Nam J, Waxman R, Emery P, Conaghan PG.

J Rheumatol. 2019 Nov 1. pii: jrheum.181385. doi: 10.3899/jrheum.181385. [Epub ahead of print]

PMID:
31676693
3.

Drosophila Cryptochrome: Variations in Blue.

Foley LE, Emery P.

J Biol Rhythms. 2019 Oct 10:748730419878290. doi: 10.1177/0748730419878290. [Epub ahead of print]

PMID:
31599203
4.

Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases.

Traylor M, Knevel R, Cui J, Taylor J, Harm-Jan W, Conaghan PG, Cope AP, Curtis C, Emery P, Newhouse S, Patel H, Steer S, Gregersen P, Shadick NA, Weinblatt ME, Van Der Helm-van Mil A, Barrett JH, Morgan AW, Lewis CM, Scott IC.

PLoS One. 2019 Oct 9;14(10):e0223246. doi: 10.1371/journal.pone.0223246. eCollection 2019.

5.

Palindromic rheumatism as part of the rheumatoid arthritis continuum.

Mankia K, Emery P.

Nat Rev Rheumatol. 2019 Oct 8. doi: 10.1038/s41584-019-0308-5. [Epub ahead of print] Review.

PMID:
31595059
6.

A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial.

Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS; SPIRIT H2H study group.

Ann Rheum Dis. 2019 Sep 28. pii: annrheumdis-2019-215386. doi: 10.1136/annrheumdis-2019-215386. [Epub ahead of print]

7.

Baseline Objective Inflammation by Magnetic Resonance Imaging as a Predictor of Therapeutic Benefit in Early, Poor Prognosis Rheumatoid Arthritis.

Ahmad HA, Baker JF, Østergaard M, Emery P, Durez P, Ye J, Banerjee S, Conaghan PG.

Arthritis Care Res (Hoboken). 2019 Sep 24. doi: 10.1002/acr.24072. [Epub ahead of print]

PMID:
31549793
8.

Validity and sensitivity to change of laser Doppler imaging as a novel objective outcome measure for cutaneous lupus erythematosus.

Md Yusof MY, Britton J, Edward S, Hensor EMA, Goodfield MJ, Laws PM, Emery P, Wittmann M, Vital EM.

Lupus. 2019 Oct;28(11):1320-1328. doi: 10.1177/0961203319873977. Epub 2019 Sep 14.

9.

Long-term follow-up of patients in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial.

Coates LC, Mahmood F, Freeston J, Emery P, Conaghan PG, Helliwell PS.

Rheumatology (Oxford). 2019 Aug 31. pii: kez369. doi: 10.1093/rheumatology/kez369. [Epub ahead of print]

PMID:
31504996
10.

Defining remission in rheumatoid arthritis: does it matter to the patient? A comparison of multi-dimensional remission criteria and patient reported outcomes.

Gul HL, Eugenio G, Rabin T, Burska A, Parmar R, Wu J, Ponchel F, Emery P.

Rheumatology (Oxford). 2019 Aug 19. pii: kez330. doi: 10.1093/rheumatology/kez330. [Epub ahead of print]

PMID:
31424522
11.

Reduction in stiffness of proximal leg muscles during the first 6 months of glucocorticoid therapy for giant cell arteritis: A pilot study using shear wave elastography.

Alfuraih AM, Tan AL, O'Connor P, Emery P, Mackie S, Wakefield RJ.

Int J Rheum Dis. 2019 Oct;22(10):1891-1899. doi: 10.1111/1756-185X.13667. Epub 2019 Jul 30.

PMID:
31364284
12.

IL-6 Mediated Transcriptional Programming of Naïve CD4+ T Cells in Early Rheumatoid Arthritis Drives Dysregulated Effector Function.

Ridgley LA, Anderson AE, Maney NJ, Naamane N, Skelton AJ, Lawson CA, Emery P, Isaacs JD, Carmody RJ, Pratt AG.

Front Immunol. 2019 Jul 3;10:1535. doi: 10.3389/fimmu.2019.01535. eCollection 2019.

13.

Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis.

Mortimer I, Bissell LA, Hensor EMA, Kozera L, Mackie SL, Burska AN, Nam JL, Keen H, Villeneuve E, Donica H, Buch MH, Conaghan PG, Emery P, Morgan AW, Andrews J.

Rheumatology (Oxford). 2019 Sep 1;58(9):1684-1686. doi: 10.1093/rheumatology/kez114. No abstract available.

14.

Muscle stiffness in rheumatoid arthritis is not altered or associated with muscle weakness: A shear wave elastography study.

Alfuraih AM, Tan AL, O'Connor P, Emery P, Wakefield RJ.

Mod Rheumatol. 2019 Aug 1:1-9. doi: 10.1080/14397595.2019.1645374. [Epub ahead of print]

PMID:
31314615
15.

Arthritis prevention in the pre-clinical phase of RA with abatacept (the APIPPRA study): a multi-centre, randomised, double-blind, parallel-group, placebo-controlled clinical trial protocol.

Al-Laith M, Jasenecova M, Abraham S, Bosworth A, Bruce IN, Buckley CD, Ciurtin C, D'Agostino MA, Emery P, Gaston H, Isaacs JD, Filer A, Fisher BA, Huizinga TWJ, Ho P, Jacklin C, Lempp H, McInnes IB, Pratt AG, Östor A, Raza K, Taylor PC, van Schaardenburg D, Shivapatham D, Wright AJ, Vasconcelos JC, Kelly J, Murphy C, Prevost AT, Cope AP.

Trials. 2019 Jul 15;20(1):429. doi: 10.1186/s13063-019-3403-7.

16.

Normal values and test-retest variability of stimulated-echo diffusion tensor imaging and fat fraction measurements in the muscle.

Farrow M, Grainger AJ, Tan AL, Buch MH, Emery P, Ridgway JP, Feiweier T, Tanner SF, Biglands J.

Br J Radiol. 2019 Sep;92(1101):20190143. doi: 10.1259/bjr.20190143. Epub 2019 Jul 12.

PMID:
31298948
17.

Determining MRI Inflammation Targets When Considering a Rheumatoid Arthritis Treat-to-Target Strategy: Results of a Randomized, Placebo-Controlled Trial.

Ahmad HA, Baker JF, Østergaard M, Ye J, Emery P, Conaghan PG.

Adv Ther. 2019 Sep;36(9):2384-2393. doi: 10.1007/s12325-019-01020-6. Epub 2019 Jul 5.

18.

The effect of deep or sustained remission on maintenance of remission after dose reduction or withdrawal of etanercept in patients with rheumatoid arthritis.

Tanaka Y, Smolen JS, Jones H, Szumski A, Marshall L, Emery P.

Arthritis Res Ther. 2019 Jul 5;21(1):164. doi: 10.1186/s13075-019-1937-4.

19.

Relative Impact of Pain and Fatigue on Work Productivity in Patients with Rheumatoid Arthritis from the RA-BEAM Baricitinib Trial.

Michaud K, Pope JE, Emery P, Zhu B, Gaich CL, DeLozier AM, Zhang X, Dickson CL, Smolen JS.

Rheumatol Ther. 2019 Sep;6(3):409-419. doi: 10.1007/s40744-019-0164-4. Epub 2019 Jun 21.

20.

Achieving Pain Control in Rheumatoid Arthritis with Baricitinib or Adalimumab Plus Methotrexate: Results from the RA-BEAM Trial.

Taylor PC, Lee YC, Fleischmann R, Takeuchi T, Perkins EL, Fautrel B, Zhu B, Quebe AK, Gaich CL, Zhang X, Dickson CL, Schlichting DE, Patel H, Durand F, Emery P.

J Clin Med. 2019 Jun 12;8(6). pii: E831. doi: 10.3390/jcm8060831.

21.

Prevalence of Periodontal Disease and Periodontopathic Bacteria in Anti-Cyclic Citrullinated Protein Antibody-Positive At-Risk Adults Without Arthritis.

Mankia K, Cheng Z, Do T, Hunt L, Meade J, Kang J, Clerehugh V, Speirs A, Tugnait A, Hensor EMA, Nam JL, Devine DA, Emery P.

JAMA Netw Open. 2019 Jun 5;2(6):e195394. doi: 10.1001/jamanetworkopen.2019.5394.

22.

Low rates of radiographic progression of structural joint damage over 2 years of baricitinib treatment in patients with rheumatoid arthritis.

van der Heijde D, Schiff M, Tanaka Y, Xie L, Meszaros G, Ishii T, Casillas M, Ortmann RA, Emery P.

RMD Open. 2019 May 10;5(1):e000898. doi: 10.1136/rmdopen-2019-000898. eCollection 2019. Erratum in: RMD Open. 2019 Jul 8;5(2):e000898corr1.

23.

Pain and depression are associated with both physical and mental fatigue independently of comorbidities and medications in primary Sjögren's syndrome.

Hackett KL, Davies K, Tarn J, Bragg R, Hargreaves B, Miyamoto S, McMeekin P, Mitchell S, Bowman S, Price EJ, Pease C, Emery P, Andrews J, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Vadivelu S, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Lendrem DW, Ng WF.

RMD Open. 2019 Apr 24;5(1):e000885. doi: 10.1136/rmdopen-2018-000885. eCollection 2019.

24.

Longterm Drug Survival of Tumor Necrosis Factor Inhibitors in Patients with Rheumatoid Arthritis.

Emery P, Vlahos B, Szczypa P, Thakur M, Jones HE, Woolcott J, Santos Estrella PV, Rolland C, Gibofsky A, Citera G, Sockalingam S, Marshall L.

J Rheumatol. 2019 Jun 1. pii: jrheum.181398. doi: 10.3899/jrheum.181398. [Epub ahead of print]

PMID:
31154413
25.

Predicting Severe Infection and Effects of Hypogammaglobulinemia During Therapy With Rituximab in Rheumatic and Musculoskeletal Diseases.

Md Yusof MY, Vital EM, McElvenny DM, Hensor EMA, Das S, Dass S, Rawstron AC, Buch MH, Emery P, Savic S.

Arthritis Rheumatol. 2019 Nov;71(11):1812-1823. doi: 10.1002/art.40937. Epub 2019 Sep 26.

PMID:
31131994
26.

Upadacitinib as monotherapy in patients with active rheumatoid arthritis and inadequate response to methotrexate (SELECT-MONOTHERAPY): a randomised, placebo-controlled, double-blind phase 3 study.

Smolen JS, Pangan AL, Emery P, Rigby W, Tanaka Y, Vargas JI, Zhang Y, Damjanov N, Friedman A, Othman AA, Camp HS, Cohen S.

Lancet. 2019 Jun 8;393(10188):2303-2311. doi: 10.1016/S0140-6736(19)30419-2. Epub 2019 May 23. Erratum in: Lancet. 2019 Jun 29;393(10191):2590.

PMID:
31130260
27.

Response to: 'Interosseous tendon inflammation of rheumatoid arthritis: what's the real meaning?' by Deng et al.

Mankia K, D'Agostino MA, Murillo-González J, Grainger A, Emery P.

Ann Rheum Dis. 2019 May 17. pii: annrheumdis-2019-215611. doi: 10.1136/annrheumdis-2019-215611. [Epub ahead of print] No abstract available.

28.

Quantifying circulating Th17 cells by qPCR: potential as diagnostic biomarker for rheumatoid arthritis.

Burska AN, Thu A, Parmar R, Bzoma I, Samans B, Raschke E, Olek S, Conaghan PG, Emery P, Ponchel F.

Rheumatology (Oxford). 2019 Nov 1;58(11):2015-2024. doi: 10.1093/rheumatology/kez162.

PMID:
31081041
29.

Re-treatment with abatacept plus methotrexate for disease flare after complete treatment withdrawal in patients with early rheumatoid arthritis: 2-year results from the AVERT study.

Emery P, Burmester GR, Bykerk VP, Combe BG, Furst DE, Maldonado MA, Huizinga TW.

RMD Open. 2019 Feb 8;5(1):e000840. doi: 10.1136/rmdopen-2018-000840. eCollection 2019.

30.

Nutrient, fibre, sorbitol and chlorogenic acid content of prunes (Prunus domestica): an updated analysis and comparison of different countries of origin and database values.

Gill SK, Lever E, Emery PW, Whelan K.

Int J Food Sci Nutr. 2019 Dec;70(8):924-931. doi: 10.1080/09637486.2019.1600664. Epub 2019 Apr 16.

PMID:
30987487
31.

MRI inflammation of the hand interosseous tendons occurs in anti-CCP-positive at-risk individuals and may precede the development of clinical synovitis.

Mankia K, D'Agostino MA, Rowbotham E, Hensor EM, Hunt L, Möller I, Miguel M, Mérida-Velasco JR, Murillo-González J, Naredo E, Nam JL, Tan AL, Freeston JE, Grainger A, Emery P.

Ann Rheum Dis. 2019 Jun;78(6):781-786. doi: 10.1136/annrheumdis-2018-214331. Epub 2019 Mar 23.

32.

First cardiovascular MRI study in individuals at risk of rheumatoid arthritis detects abnormal aortic stiffness suggesting an anti-citrullinated peptide antibody-mediated role for accelerated atherosclerosis.

Fent G, Mankia K, Erhayiem B, Hunt L, Nam JL, Bissell LA, Foley JR, Chew PG, Brown LE, Greenwood JP, Emery P, Plein S, Buch MH.

Ann Rheum Dis. 2019 Aug;78(8):1138-1140. doi: 10.1136/annrheumdis-2018-214975. Epub 2019 Mar 9. No abstract available.

33.

Evolving treatment paradigms for rheumatoid arthritis: Translating comprehensive patient evaluations into personalized therapy.

Calabrese LH, Emery P, Kivitz AJ, Tesser JRP.

Semin Arthritis Rheum. 2019 Jan 23. pii: S0049-0172(19)30030-7. doi: 10.1016/j.semarthrit.2019.01.008. [Epub ahead of print] No abstract available.

PMID:
30850126
34.

Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis.

Hensor EMA, McKeigue P, Ling SF, Colombo M, Barrett JH, Nam JL, Freeston J, Buch MH, Spiliopoulou A, Agakov F, Kelly S, Lewis MJ, Verstappen SMM, MacGregor AJ, Viatte S, Barton A, Pitzalis C, Emery P, Conaghan PG, Morgan AW.

Rheumatology (Oxford). 2019 Mar 1. pii: kez049. doi: 10.1093/rheumatology/kez049. [Epub ahead of print]

35.

Muscle shear wave elastography in idiopathic inflammatory myopathies: a case-control study with MRI correlation.

Alfuraih AM, O'Connor P, Tan AL, Hensor EMA, Ladas A, Emery P, Wakefield RJ.

Skeletal Radiol. 2019 Aug;48(8):1209-1219. doi: 10.1007/s00256-019-03175-3. Epub 2019 Feb 27.

36.

The effect of ageing on shear wave elastography muscle stiffness in adults.

Alfuraih AM, Tan AL, O'Connor P, Emery P, Wakefield RJ.

Aging Clin Exp Res. 2019 Dec;31(12):1755-1763. doi: 10.1007/s40520-019-01139-0. Epub 2019 Feb 14.

37.

Correction to: On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2019 May;39(5):945. doi: 10.1007/s00296-018-4232-9.

38.

Clinical trial and 'real-world' data support switching from a bio-originator to its biosimilar.

Kay J, Dörner T, Emery P, Kvien TK, Breedveld FC.

Ann Rheum Dis. 2019 Jan 18. pii: annrheumdis-2018-214994. doi: 10.1136/annrheumdis-2018-214994. [Epub ahead of print] No abstract available.

39.

MRI and Dose Selection in a Phase II Trial of Baricitinib with Conventional Synthetic Disease-modifying Antirheumatic Drugs in Rheumatoid Arthritis.

Peterfy C, DiCarlo J, Emery P, Genovese MC, Keystone EC, Taylor PC, Schlichting DE, Beattie SD, Luchi M, Macias W.

J Rheumatol. 2019 Aug;46(8):887-895. doi: 10.3899/jrheum.171469. Epub 2019 Jan 15.

40.

Responsiveness of clinical and ultrasound outcome measures in musculoskeletal systemic lupus erythematosus.

Mahmoud K, Zayat AS, Yusof Y, Hensor E, Conaghan PG, Emery P, Vital EM.

Rheumatology (Oxford). 2019 Jan 3. doi: 10.1093/rheumatology/key422. [Epub ahead of print]

41.

Safety and tolerability of subcutaneous sarilumab and intravenous tocilizumab in patients with rheumatoid arthritis.

Emery P, Rondon J, Parrino J, Lin Y, Pena-Rossi C, van Hoogstraten H, Graham NMH, Liu N, Paccaly A, Wu R, Spindler A.

Rheumatology (Oxford). 2019 May 1;58(5):849-858. doi: 10.1093/rheumatology/key361.

42.

Secukinumab shows sustained efficacy and low structural progression in ankylosing spondylitis: 4-year results from the MEASURE 1 study.

Braun J, Baraliakos X, Deodhar A, Poddubnyy D, Emery P, Delicha EM, Talloczy Z, Porter B.

Rheumatology (Oxford). 2019 May 1;58(5):859-868. doi: 10.1093/rheumatology/key375.

43.

Guided inquiry activity linking thermodynamic parameters of protein unfolding to structure using differential scanning fluorimetry data in the biophysical chemistry classroom.

Emery P, Yezierski EJ, Page RC.

Biochem Mol Biol Educ. 2019 Jan;47(1):67-75. doi: 10.1002/bmb.21198. Epub 2018 Dec 22.

PMID:
30578703
44.

Response to: 'Ultrasound findings in palindromic rheumatism' by Sanmarti et al.

Mankia K, D'Agostino MA, Emery P.

Ann Rheum Dis. 2018 Dec 21. pii: annrheumdis-2018-214867. doi: 10.1136/annrheumdis-2018-214867. [Epub ahead of print] No abstract available.

45.

Regression of Peripheral Subclinical Enthesopathy in Therapy-Naive Patients Treated With Ustekinumab for Moderate-to-Severe Chronic Plaque Psoriasis: A Fifty-Two-Week, Prospective, Open-Label Feasibility Study.

Savage L, Goodfield M, Horton L, Watad A, Hensor E, Emery P, Wakefield R, Wittmann M, McGonagle D.

Arthritis Rheumatol. 2019 Apr;71(4):626-631. doi: 10.1002/art.40778. Epub 2019 Mar 4.

PMID:
30468001
46.

Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities.

Baraliakos X, Conaghan PG, D'Agostino MA, Maksymowych W, Naredo E, Ostergaard M, Schett G, Emery P.

Eur J Rheumatol. 2019 Jan;6(1):38-47. doi: 10.5152/eurjrheum.2018.18121. Review.

47.

Safety evaluation of adalimumab in immune-mediated inflammatory disorders: a rheumatological point of view.

Duquenne L, Gul H, Emery P.

Expert Opin Drug Saf. 2019 Jan;18(1):11-19. doi: 10.1080/14740338.2018.1549541. Epub 2018 Dec 17. Review.

PMID:
30444672
48.

Recent advances in ankylosing spondylitis: understanding the disease and management.

Garcia-Montoya L, Gul H, Emery P.

F1000Res. 2018 Sep 21;7. pii: F1000 Faculty Rev-1512. doi: 10.12688/f1000research.14956.1. eCollection 2018. Review.

49.

On-drug and drug-free remission by baseline symptom duration: abatacept with methotrexate in patients with early rheumatoid arthritis.

Bykerk VP, Burmester GR, Combe BG, Furst DE, Huizinga TWJ, Ahmad HA, Emery P.

Rheumatol Int. 2018 Dec;38(12):2225-2231. doi: 10.1007/s00296-018-4173-3. Epub 2018 Oct 20. Erratum in: Rheumatol Int. 2019 Feb 5;:.

50.

Identification of a distinct imaging phenotype may improve the management of palindromic rheumatism.

Mankia K, D'Agostino MA, Wakefield RJ, Nam JL, Mahmood W, Grainger AJ, Emery P.

Ann Rheum Dis. 2019 Jan;78(1):43-50. doi: 10.1136/annrheumdis-2018-214175. Epub 2018 Oct 8.

Supplemental Content

Support Center